Share Price and Basic Stock Data
Last Updated: November 28, 2025, 8:37 am
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Krebs Biochemicals & Industries Ltd operates within the pharmaceuticals sector, recording a market capitalization of ₹143 Cr. The company’s recent revenue trends exhibit volatility, with quarterly sales fluctuating significantly. For instance, in June 2022, sales stood at ₹10.64 Cr, which peaked at ₹20.94 Cr in September 2022 before declining to ₹9.09 Cr in December 2022. The sales trajectory indicates a recovery with ₹14.89 Cr reported in September 2023, although it dropped to ₹12.98 Cr in December 2023. The trailing twelve-month revenue is ₹27 Cr, a stark contrast to prior years, showcasing a decline from ₹60 Cr in March 2022 to ₹52 Cr in March 2023. This decline raises concerns about the sustainability of revenue generation, particularly given the high operating profit margin (OPM) of -38.14%, reflecting ongoing challenges in maintaining profitability amidst fluctuating sales.
Profitability and Efficiency Metrics
Krebs Biochemicals has faced significant profitability challenges, illustrated by a net profit of -₹27 Cr. The company’s operating profit has consistently remained negative, with the most recent quarterly figure reaching -₹5.41 Cr in March 2025. The operating profit margin has shown no signs of recovery, with averages around -38.14% in the latest quarter. Efficiency metrics are equally concerning; the cash conversion cycle (CCC) has deteriorated to -795 days, indicating severe inefficiencies in managing working capital. The interest coverage ratio (ICR) is reported at 2.42x, suggesting that while the company can cover its interest obligations, it does so with little margin. The return on capital employed (ROCE) stands at 30.1%, which is commendable; however, the negative net profit and operational losses overshadow this metric, indicating that the capital’s utilization is not translating into profitable operations.
Balance Sheet Strength and Financial Ratios
The balance sheet of Krebs Biochemicals reflects significant financial strain, with total borrowings of ₹219 Cr against reserves of -₹179 Cr. This negative reserve indicates a precarious financial position, as liabilities exceed equity, contributing to a total debt-to-equity ratio of -0.56. The company’s current ratio is alarmingly low at 0.09, suggesting liquidity issues, which could hinder operational flexibility. Moreover, the price-to-book value (P/BV) ratio is reported at -0.98x, indicating that the market values the company below its book value, a sign of lack of investor confidence. The consistent decline in net profit and the increase in borrowings over the years—from ₹183 Cr in March 2023 to ₹219 Cr in March 2025—highlights the company’s mounting financial obligations, which may pose risks to its long-term viability.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Krebs Biochemicals reveals a dominant promoter holding of 72.74%, suggesting strong control by insiders. Institutional ownership is notably low, with Foreign Institutional Investors (FIIs) holding just 0.50%. The public shareholding stands at 26.76%, which indicates a lack of broader investor interest. The total number of shareholders has seen fluctuations, dropping to 8,912 by September 2025 from 9,294 in December 2022. This decline in shareholder numbers could reflect waning confidence in the company’s prospects, driven by its poor financial performance. The absence of dividends, as indicated by a consistent dividend payout of 0%, further emphasizes the company’s focus on stabilizing its financial health rather than returning capital to shareholders. This concentration of ownership and lack of institutional backing may limit the company’s ability to attract new investments.
Outlook, Risks, and Final Insight
Krebs Biochemicals faces a challenging outlook characterized by significant operational inefficiencies, high debt levels, and a lack of profitability. The persistent negative net profit and low liquidity ratios are critical risks that could hinder future growth. However, the strong promoter holding presents a potential strength, as it may provide stability during turbulent times. If the company can successfully implement strategic measures to enhance operational efficiency and revenue generation, there may be an opportunity for recovery. Conversely, continued financial mismanagement, coupled with the current economic climate and market conditions, could lead to further declines in performance. Stakeholders should closely monitor the company’s financial health and operational strategies, as these will be pivotal in determining its future trajectory and ability to navigate its current challenges.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Krebs Biochemicals & Industries Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 164 Cr. | 130 | 247/84.3 | 36.2 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,467 Cr. | 410 | 479/192 | 92.5 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.5 Cr. | 46.5 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 41.0 Cr. | 28.0 | 29.3/17.0 | 97.7 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,336.40 Cr | 1,175.88 | 52.22 | 202.44 | 0.35% | 16.29% | 15.20% | 6.10 |
All Competitor Stocks of Krebs Biochemicals & Industries Ltd
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 10.64 | 20.94 | 9.09 | 11.46 | 10.58 | 14.89 | 12.98 | 11.97 | 12.89 | 12.86 | 11.47 | 6.10 | 5.48 |
| Expenses | 16.91 | 22.84 | 12.07 | 16.08 | 13.20 | 15.79 | 15.07 | 15.09 | 15.08 | 15.58 | 16.18 | 11.51 | 7.57 |
| Operating Profit | -6.27 | -1.90 | -2.98 | -4.62 | -2.62 | -0.90 | -2.09 | -3.12 | -2.19 | -2.72 | -4.71 | -5.41 | -2.09 |
| OPM % | -58.93% | -9.07% | -32.78% | -40.31% | -24.76% | -6.04% | -16.10% | -26.07% | -16.99% | -21.15% | -41.06% | -88.69% | -38.14% |
| Other Income | 0.13 | 0.27 | 0.02 | 0.19 | 0.04 | 0.17 | 0.03 | 0.21 | 0.03 | 0.09 | 0.25 | 0.34 | 0.01 |
| Interest | 0.30 | 0.74 | 0.90 | 1.03 | 1.10 | 1.13 | 1.19 | 1.27 | 1.32 | 1.42 | 1.56 | 1.61 | 1.65 |
| Depreciation | 1.69 | 1.69 | 1.69 | 1.48 | 1.65 | 1.71 | 1.73 | 1.67 | 1.69 | 1.71 | 1.72 | 1.57 | 1.60 |
| Profit before tax | -8.13 | -4.06 | -5.55 | -6.94 | -5.33 | -3.57 | -4.98 | -5.85 | -5.17 | -5.76 | -7.74 | -8.25 | -5.33 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.24% | 0.00% |
| Net Profit | -8.14 | -4.06 | -5.55 | -6.94 | -5.33 | -3.57 | -4.98 | -5.85 | -5.17 | -5.76 | -7.74 | -8.27 | -5.32 |
| EPS in Rs | -3.78 | -1.88 | -2.57 | -3.22 | -2.47 | -1.66 | -2.31 | -2.71 | -2.40 | -2.67 | -3.59 | -3.84 | -2.47 |
Last Updated: August 20, 2025, 8:00 am
Below is a detailed analysis of the quarterly data for Krebs Biochemicals & Industries Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 5.48 Cr.. The value appears to be declining and may need further review. It has decreased from 6.10 Cr. (Mar 2025) to 5.48 Cr., marking a decrease of 0.62 Cr..
- For Expenses, as of Jun 2025, the value is 7.57 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 11.51 Cr. (Mar 2025) to 7.57 Cr., marking a decrease of 3.94 Cr..
- For Operating Profit, as of Jun 2025, the value is -2.09 Cr.. The value appears strong and on an upward trend. It has increased from -5.41 Cr. (Mar 2025) to -2.09 Cr., marking an increase of 3.32 Cr..
- For OPM %, as of Jun 2025, the value is -38.14%. The value appears strong and on an upward trend. It has increased from -88.69% (Mar 2025) to -38.14%, marking an increase of 50.55%.
- For Other Income, as of Jun 2025, the value is 0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 0.34 Cr. (Mar 2025) to 0.01 Cr., marking a decrease of 0.33 Cr..
- For Interest, as of Jun 2025, the value is 1.65 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.61 Cr. (Mar 2025) to 1.65 Cr., marking an increase of 0.04 Cr..
- For Depreciation, as of Jun 2025, the value is 1.60 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.57 Cr. (Mar 2025) to 1.60 Cr., marking an increase of 0.03 Cr..
- For Profit before tax, as of Jun 2025, the value is -5.33 Cr.. The value appears strong and on an upward trend. It has increased from -8.25 Cr. (Mar 2025) to -5.33 Cr., marking an increase of 2.92 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value appears to be improving (decreasing) as expected. It has decreased from 0.24% (Mar 2025) to 0.00%, marking a decrease of 0.24%.
- For Net Profit, as of Jun 2025, the value is -5.32 Cr.. The value appears strong and on an upward trend. It has increased from -8.27 Cr. (Mar 2025) to -5.32 Cr., marking an increase of 2.95 Cr..
- For EPS in Rs, as of Jun 2025, the value is -2.47. The value appears strong and on an upward trend. It has increased from -3.84 (Mar 2025) to -2.47, marking an increase of 1.37.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 5:00 am
| Metric | Sep 2014n n 15m | Mar 2015n n 6m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 1 | 3 | 34 | 48 | 33 | 54 | 60 | 52 | 50 | 43 | 27 |
| Expenses | 4 | 5 | 14 | 11 | 41 | 58 | 52 | 71 | 94 | 68 | 59 | 58 | 42 |
| Operating Profit | -4 | -5 | -12 | -8 | -8 | -10 | -19 | -18 | -34 | -16 | -9 | -15 | -15 |
| OPM % | -1,088% | -248% | -22% | -20% | -56% | -33% | -57% | -30% | -17% | -35% | -55% | ||
| Other Income | 0 | 3 | 1 | -0 | -1 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 |
| Interest | 0 | 4 | 1 | 3 | 5 | 6 | 6 | 6 | 5 | 3 | 5 | 6 | 7 |
| Depreciation | 0 | 2 | 4 | 4 | 4 | 4 | 5 | 5 | 6 | 7 | 7 | 7 | 7 |
| Profit before tax | -4 | -8 | -16 | -16 | -18 | -20 | -29 | -28 | -45 | -25 | -20 | -27 | -27 |
| Tax % | 10% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | |
| Net Profit | -4 | -8 | -16 | -16 | -18 | -20 | -29 | -28 | -45 | -25 | -20 | -27 | -27 |
| EPS in Rs | -3.78 | -6.82 | -10.33 | -9.67 | -10.73 | -12.03 | -16.04 | -14.45 | -20.65 | -11.45 | -9.15 | -12.50 | -12.75 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | -12.50% | -11.11% | -45.00% | 3.45% | -60.71% | 44.44% | 20.00% | -35.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -12.50% | 1.39% | -33.89% | 48.45% | -64.16% | 105.16% | -24.44% | -55.00% |
Krebs Biochemicals & Industries Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 5% |
| 3 Years: | -10% |
| TTM: | -32% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 1% |
| 3 Years: | 12% |
| TTM: | -38% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -4% |
| 3 Years: | -19% |
| 1 Year: | -15% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Last Updated: September 5, 2025, 9:20 am
Balance Sheet
Last Updated: November 9, 2025, 2:23 pm
| Month | Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 13 | 14 | 14 | 17 | 18 | 20 | 22 | 22 | 22 | 22 | 22 |
| Reserves | -6 | 9 | -0 | -12 | -32 | -31 | -43 | -62 | -97 | -121 | -141 | -168 | -179 |
| Borrowings | 93 | 61 | 31 | 48 | 56 | 53 | 66 | 111 | 143 | 183 | 194 | 212 | 219 |
| Other Liabilities | 41 | 29 | 73 | 73 | 87 | 103 | 93 | 91 | 122 | 91 | 104 | 103 | 106 |
| Total Liabilities | 138 | 108 | 116 | 122 | 126 | 142 | 134 | 159 | 190 | 175 | 178 | 169 | 168 |
| Fixed Assets | 58 | 58 | 93 | 102 | 101 | 101 | 105 | 118 | 139 | 147 | 150 | 146 | 146 |
| CWIP | -0 | -0 | 11 | 4 | 4 | 3 | 4 | 12 | 8 | 4 | 2 | 3 | 1 |
| Investments | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Other Assets | 80 | 50 | 13 | 16 | 21 | 38 | 24 | 29 | 43 | 24 | 26 | 20 | 20 |
| Total Assets | 138 | 108 | 116 | 122 | 126 | 142 | 134 | 159 | 190 | 175 | 178 | 169 | 168 |
Below is a detailed analysis of the balance sheet data for Krebs Biochemicals & Industries Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 22.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 22.00 Cr..
- For Reserves, as of Sep 2025, the value is -179.00 Cr.. The value appears to be worsening (becoming more negative). It has deteriorated from -168.00 Cr. (Mar 2025) to -179.00 Cr., marking a decline of 11.00 Cr..
- For Borrowings, as of Sep 2025, the value is 219.00 Cr.. The value appears to be increasing, which may not be favorable. However, Reserves are negative, which is a major warning sign. It has increased from 212.00 Cr. (Mar 2025) to 219.00 Cr., marking an increase of 7.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 106.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 103.00 Cr. (Mar 2025) to 106.00 Cr., marking an increase of 3.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 168.00 Cr.. The value appears to be improving (decreasing). It has decreased from 169.00 Cr. (Mar 2025) to 168.00 Cr., marking a decrease of 1.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 146.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 146.00 Cr..
- For CWIP, as of Sep 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3.00 Cr. (Mar 2025) to 1.00 Cr., marking a decrease of 2.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 20.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 20.00 Cr..
- For Total Assets, as of Sep 2025, the value is 168.00 Cr.. The value appears to be declining and may need further review. It has decreased from 169.00 Cr. (Mar 2025) to 168.00 Cr., marking a decrease of 1.00 Cr..
However, the Borrowings (219.00 Cr.) are higher than the Reserves (-179.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2015n n 6m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2014n n 15m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -5.00 | -43.00 | -56.00 | -64.00 | -63.00 | -85.00 | -129.00 | -177.00 | -199.00 | -203.00 | -227.00 | -4.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 10 | 180 | 3 | 22 | 2 | 2 | 5 | 4 | 14 | 0 | ||
| Inventory Days | 14,704 | 2,162 | 337 | 142 | 345 | 234 | 230 | 170 | 543 | 396 | ||
| Days Payable | 32,250 | 4,360 | 510 | 339 | 521 | 292 | 340 | 217 | 1,051 | 1,192 | ||
| Cash Conversion Cycle | -17,536 | -2,018 | -170 | -175 | -174 | -57 | -106 | -44 | -494 | -795 | ||
| Working Capital Days | -6,532 | -2,132 | -275 | -315 | -267 | -187 | -261 | -232 | -322 | -787 | ||
| ROCE % | -4% | -8% | -26% | -26% | -26% | -36% | -57% | -40% | -57% | -29% | -19% | -30% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -12.49 | -9.16 | -11.30 | -20.81 | -14.53 |
| Diluted EPS (Rs.) | -12.49 | -9.16 | -11.30 | -20.81 | -14.53 |
| Cash EPS (Rs.) | -9.39 | -6.01 | -8.41 | -17.73 | -11.84 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | -67.83 | -55.29 | -46.13 | -34.83 | -21.78 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | -67.83 | -55.29 | -46.13 | -34.83 | -21.78 |
| Revenue From Operations / Share (Rs.) | 20.09 | 23.39 | 24.18 | 27.69 | 27.37 |
| PBDIT / Share (Rs.) | -6.64 | -3.84 | -7.03 | -15.23 | -8.64 |
| PBIT / Share (Rs.) | -9.74 | -6.97 | -10.07 | -18.15 | -11.25 |
| PBT / Share (Rs.) | -12.49 | -9.15 | -11.45 | -20.65 | -14.45 |
| Net Profit / Share (Rs.) | -12.49 | -9.15 | -11.45 | -20.65 | -14.45 |
| PBDIT Margin (%) | -33.06 | -16.40 | -29.07 | -55.00 | -31.57 |
| PBIT Margin (%) | -48.50 | -29.82 | -41.65 | -65.55 | -41.11 |
| PBT Margin (%) | -62.16 | -39.12 | -47.36 | -74.58 | -52.80 |
| Net Profit Margin (%) | -62.19 | -39.12 | -47.36 | -74.58 | -52.80 |
| Return on Capital Employeed (%) | -32.07 | -12.92 | -17.25 | -35.02 | -19.88 |
| Return On Assets (%) | -15.93 | -11.07 | -14.11 | -23.45 | -17.81 |
| Long Term Debt / Equity (X) | -0.21 | -0.44 | -0.43 | -0.03 | -2.35 |
| Total Debt / Equity (X) | -0.56 | -0.53 | -0.53 | -0.17 | -2.35 |
| Asset Turnover Ratio (%) | 0.24 | 0.28 | 0.28 | 0.34 | 0.36 |
| Current Ratio (X) | 0.09 | 0.28 | 0.32 | 0.45 | 0.44 |
| Quick Ratio (X) | 0.04 | 0.12 | 0.08 | 0.12 | 0.09 |
| Inventory Turnover Ratio (X) | 5.47 | 0.49 | 0.81 | 2.19 | 1.62 |
| Interest Coverage Ratio (X) | -2.42 | -1.76 | -5.10 | -6.09 | -2.70 |
| Interest Coverage Ratio (Post Tax) (X) | -3.56 | -3.21 | -7.30 | -7.26 | -3.52 |
| Enterprise Value (Cr.) | 356.07 | 324.85 | 304.75 | 451.99 | 274.16 |
| EV / Net Operating Revenue (X) | 8.22 | 6.44 | 5.85 | 7.57 | 5.11 |
| EV / EBITDA (X) | -24.86 | -39.27 | -20.10 | -13.76 | -16.17 |
| MarketCap / Net Operating Revenue (X) | 3.32 | 2.61 | 2.33 | 5.18 | 3.25 |
| Price / BV (X) | -0.98 | -1.10 | -1.22 | -4.12 | -4.08 |
| Price / Net Operating Revenue (X) | 3.32 | 2.61 | 2.33 | 5.18 | 3.25 |
| EarningsYield | -0.18 | -0.14 | -0.20 | -0.14 | -0.16 |
After reviewing the key financial ratios for Krebs Biochemicals & Industries Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -12.49. This value is below the healthy minimum of 5. It has decreased from -9.16 (Mar 24) to -12.49, marking a decrease of 3.33.
- For Diluted EPS (Rs.), as of Mar 25, the value is -12.49. This value is below the healthy minimum of 5. It has decreased from -9.16 (Mar 24) to -12.49, marking a decrease of 3.33.
- For Cash EPS (Rs.), as of Mar 25, the value is -9.39. This value is below the healthy minimum of 3. It has decreased from -6.01 (Mar 24) to -9.39, marking a decrease of 3.38.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -67.83. It has decreased from -55.29 (Mar 24) to -67.83, marking a decrease of 12.54.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -67.83. It has decreased from -55.29 (Mar 24) to -67.83, marking a decrease of 12.54.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 20.09. It has decreased from 23.39 (Mar 24) to 20.09, marking a decrease of 3.30.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -6.64. This value is below the healthy minimum of 2. It has decreased from -3.84 (Mar 24) to -6.64, marking a decrease of 2.80.
- For PBIT / Share (Rs.), as of Mar 25, the value is -9.74. This value is below the healthy minimum of 0. It has decreased from -6.97 (Mar 24) to -9.74, marking a decrease of 2.77.
- For PBT / Share (Rs.), as of Mar 25, the value is -12.49. This value is below the healthy minimum of 0. It has decreased from -9.15 (Mar 24) to -12.49, marking a decrease of 3.34.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -12.49. This value is below the healthy minimum of 2. It has decreased from -9.15 (Mar 24) to -12.49, marking a decrease of 3.34.
- For PBDIT Margin (%), as of Mar 25, the value is -33.06. This value is below the healthy minimum of 10. It has decreased from -16.40 (Mar 24) to -33.06, marking a decrease of 16.66.
- For PBIT Margin (%), as of Mar 25, the value is -48.50. This value is below the healthy minimum of 10. It has decreased from -29.82 (Mar 24) to -48.50, marking a decrease of 18.68.
- For PBT Margin (%), as of Mar 25, the value is -62.16. This value is below the healthy minimum of 10. It has decreased from -39.12 (Mar 24) to -62.16, marking a decrease of 23.04.
- For Net Profit Margin (%), as of Mar 25, the value is -62.19. This value is below the healthy minimum of 5. It has decreased from -39.12 (Mar 24) to -62.19, marking a decrease of 23.07.
- For Return on Capital Employeed (%), as of Mar 25, the value is -32.07. This value is below the healthy minimum of 10. It has decreased from -12.92 (Mar 24) to -32.07, marking a decrease of 19.15.
- For Return On Assets (%), as of Mar 25, the value is -15.93. This value is below the healthy minimum of 5. It has decreased from -11.07 (Mar 24) to -15.93, marking a decrease of 4.86.
- For Long Term Debt / Equity (X), as of Mar 25, the value is -0.21. This value is below the healthy minimum of 0.2. It has increased from -0.44 (Mar 24) to -0.21, marking an increase of 0.23.
- For Total Debt / Equity (X), as of Mar 25, the value is -0.56. This value is within the healthy range. It has decreased from -0.53 (Mar 24) to -0.56, marking a decrease of 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.24. It has decreased from 0.28 (Mar 24) to 0.24, marking a decrease of 0.04.
- For Current Ratio (X), as of Mar 25, the value is 0.09. This value is below the healthy minimum of 1.5. It has decreased from 0.28 (Mar 24) to 0.09, marking a decrease of 0.19.
- For Quick Ratio (X), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 1. It has decreased from 0.12 (Mar 24) to 0.04, marking a decrease of 0.08.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.47. This value is within the healthy range. It has increased from 0.49 (Mar 24) to 5.47, marking an increase of 4.98.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -2.42. This value is below the healthy minimum of 3. It has decreased from -1.76 (Mar 24) to -2.42, marking a decrease of 0.66.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -3.56. This value is below the healthy minimum of 3. It has decreased from -3.21 (Mar 24) to -3.56, marking a decrease of 0.35.
- For Enterprise Value (Cr.), as of Mar 25, the value is 356.07. It has increased from 324.85 (Mar 24) to 356.07, marking an increase of 31.22.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 8.22. This value exceeds the healthy maximum of 3. It has increased from 6.44 (Mar 24) to 8.22, marking an increase of 1.78.
- For EV / EBITDA (X), as of Mar 25, the value is -24.86. This value is below the healthy minimum of 5. It has increased from -39.27 (Mar 24) to -24.86, marking an increase of 14.41.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.32. This value exceeds the healthy maximum of 3. It has increased from 2.61 (Mar 24) to 3.32, marking an increase of 0.71.
- For Price / BV (X), as of Mar 25, the value is -0.98. This value is below the healthy minimum of 1. It has increased from -1.10 (Mar 24) to -0.98, marking an increase of 0.12.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.32. This value exceeds the healthy maximum of 3. It has increased from 2.61 (Mar 24) to 3.32, marking an increase of 0.71.
- For EarningsYield, as of Mar 25, the value is -0.18. This value is below the healthy minimum of 5. It has decreased from -0.14 (Mar 24) to -0.18, marking a decrease of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Krebs Biochemicals & Industries Ltd:
- Net Profit Margin: -62.19%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -32.07% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -3.56
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.04
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 52.22)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: -0.56
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -62.19%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Kothapalli Village, Kasimkota Mandal, Anakapalli Dist. Andhra Pradesh 531031 | investors@krebsbiochem.com www.krebsbiochem.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. R T Ravi | Chairman & Non-Exe.Director |
| Mr. Manish Kumar Jain | Managing Director & CEO |
| Mr. P K Bhattacharyya | Non Executive Director |
| Mr. Avinash Ravi | Non Executive Director |
| Mr. P M Kathariya | Independent Director |
| Ms. Dipti Shah | Independent Director |
| Mr. Satya Prakash Chigurupati | Independent Director |
| Mr. Sumanth Karlapudi | Independent Director |
FAQ
What is the intrinsic value of Krebs Biochemicals & Industries Ltd?
Krebs Biochemicals & Industries Ltd's intrinsic value (as of 28 November 2025) is 134.40 which is 106.13% higher the current market price of 65.20, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 141 Cr. market cap, FY2025-2026 high/low of 116/63.6, reserves of ₹-179 Cr, and liabilities of 168 Cr.
What is the Market Cap of Krebs Biochemicals & Industries Ltd?
The Market Cap of Krebs Biochemicals & Industries Ltd is 141 Cr..
What is the current Stock Price of Krebs Biochemicals & Industries Ltd as on 28 November 2025?
The current stock price of Krebs Biochemicals & Industries Ltd as on 28 November 2025 is 65.2.
What is the High / Low of Krebs Biochemicals & Industries Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Krebs Biochemicals & Industries Ltd stocks is 116/63.6.
What is the Stock P/E of Krebs Biochemicals & Industries Ltd?
The Stock P/E of Krebs Biochemicals & Industries Ltd is .
What is the Book Value of Krebs Biochemicals & Industries Ltd?
The Book Value of Krebs Biochemicals & Industries Ltd is 73.2.
What is the Dividend Yield of Krebs Biochemicals & Industries Ltd?
The Dividend Yield of Krebs Biochemicals & Industries Ltd is 0.00 %.
What is the ROCE of Krebs Biochemicals & Industries Ltd?
The ROCE of Krebs Biochemicals & Industries Ltd is 30.1 %.
What is the ROE of Krebs Biochemicals & Industries Ltd?
The ROE of Krebs Biochemicals & Industries Ltd is %.
What is the Face Value of Krebs Biochemicals & Industries Ltd?
The Face Value of Krebs Biochemicals & Industries Ltd is 10.0.